Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease.

International journal of molecular sciences·2026
Same author

Prevalence and Association of Liver Steatosis and Non-Alcoholic Pancreatic Steatosis in Very High Cardiovascular Risk.

Diseases (Basel, Switzerland)·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease after Pancreatoduodenectomy: an Underestimated Metabolic Complication Driven by Unique Pathophysiological Mechanisms.

Journal of gastrointestinal cancer·2026
Same author

Bariatric Surgery in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Long-Term Benefits for Liver Health.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Mini-Review: The Detoxification Effects of Black Radish in Metabolically Dysfunctional-Associated Fatty Liver Disease.

International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition·2026
Same author

Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond.

Journal of clinical and experimental hepatology·2025
Same journal

Pragmatism should not eclipse validation in expanded HBV management for Latin America: response.

Annals of hepatology·2026
Same journal

Alcohol-associated liver disease in Asian Americans: the case for disaggregated analysis.

Annals of hepatology·2026
Same journal

Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation.

Annals of hepatology·2026
Same journal

Alcohol-associated liver disease in the MENA region: A 16-country survey of healthcare provider perspectives.

Annals of hepatology·2026
Same journal

Stem cell therapies for liver cirrhosis: a GRADE evaluation through a systematic review.

Annals of hepatology·2026
Same journal

Role of spot urine analyses in patients with cirrhosis and ascites as the single first decompensation event.

Annals of hepatology·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Atherosclerosis and chronic hepatitis C

Luis D Carrillo-Córdova1, Misael Uribe, Nahum Méndez-Sánchez

  • 1Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.

Annals of Hepatology
|June 16, 2012
PubMed
Summary

No abstract available in PubMed .

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Related Experiment Videos

Last Updated: May 21, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017